DreamCIS, Inc.
KKRX:2232504,165.00
KRW
+75.00
(+1.83%)
DreamCIS, Inc.
KRX:223250
(Korea Stock Exchange)
Recent
price
4,165.00
P/E
ratio
240.93
div
yld
- -
ROIC.AI
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.- Similar Companies
- Business
- DreamCIS, Inc. is a South Korea-based contract research organization that provides comprehensive clinical development, regulatory consulting, and post-marketing clinical trial services to pharmaceutical, biotechnology, medical device, and healthcare companies. Founded in 2000 and headquartered in Seoul, South Korea, the company operates as a subsidiary of Hangzhou Tigermed Consulting Co., Ltd., serving domestic and international clients across the Asia-Pacific region, North America, and Europe. The company offers end-to-end clinical trial solutions, including: Phase I through Phase IV clinical trial design, execution, monitoring, and project management; post-marketing surveillance, observational research, and real-world evidence studies; regulatory affairs consulting, protocol design, investigational new drug application support, and new drug application filings; clinical data management, electronic data capture administration, and biostatistical analysis; medical writing, clinical study report generation, and regulatory dossier preparation; pharmacovigilance, adverse event management, and drug safety surveillance; quality assurance audits and good clinical practice compliance verification; and specialized clinical evaluation, regulatory approval consulting, and clinical investigations for medical devices, in vitro diagnostics, and digital therapeutics. In recent developments, DreamCIS, Inc. has expanded its operational capabilities by integrating decentralized clinical trial technologies, artificial intelligence-powered clinical data analytics, and digital patient recruitment solutions into its clinical infrastructure. The company has also strengthened its cross-border clinical trial partnerships through its parent group network to support South Korean biotechnology firms in multinational clinical programs, while establishing strategic investment and clinical co-development agreements with emerging biopharmaceutical developers to broaden its early-stage clinical consulting and pipeline acceleration services.